[
    [
        {
            "time": "",
            "original_text": "摩通：首予药明康德(02359.HK)“增持”评级 目标价115港元",
            "features": {
                "keywords": [
                    "药明康德",
                    "增持",
                    "目标价",
                    "115港元"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "摩通：首予药明康德(02359.HK)“增持”评级 目标价115港元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]